Heid, Irina
Münch, Corinna
Karakaya, Sinan
Lueong, Smiths S.
Winkelkotte, Alina M.
Liffers, Sven T.
Godfrey, Laura
Cheung, Phyllis F. Y.
Savvatakis, Konstantinos
Topping, Geoffrey J.
Englert, Florian
Kritzner, Lukas
Grashei, Martin
Tannapfel, Andrea
Viebahn, Richard
Wolters, Heiner
Uhl, Waldemar
Vangala, Deepak
Smeets, Esther M. M.
Aarntzen, Erik H. J. G.
Rauh, Daniel
Weichert, Wilko
Hoheisel, Jörg D.
Hahn, Stephan A.
Schilling, Franz
Braren, Rickmer
Trajkovic-Arsic, Marija
Siveke, Jens T.
Funding for this research was provided by:
SFB-Initiative 824 (collaborative research center), “Imaging for Selection, Monitoring and Individualization of Cancer Therapies” (SFB 824, SFB 824, SFB 824, SFB 824, SFB 824, SFB 824, SFB 824)
Wilhelm-Sander Stiftung , Germany (2019.008.1, 2019.008.1, 2019.008.1)
Deutschen Konsortium für Translationale Krebsforschung
Deutsche Forschungsgemeinschaft (#405344257 (SI 1549/3-2); SI1549/4-1, #405344257 (SI 1549/3-2); SI1549/4-1, #405344257 (SI 1549/3-2); SI1549/4-1, #405344257 (SI 1549/3-2); SI1549/4-1)
Deutsche Krebshilfe (#70112505/PIPAC, #70113834/PREDICT-PACA, #70112505/PIPAC, #70113834/PREDICT-PACA, #70112505/PIPAC, #70113834/PREDICT-PACA, #70112505/PIPAC, #70113834/PREDICT-PACA)
German Federal Ministry of Education and Research (BMBF; 01KD2206A/SATURN3, BMBF; 01KD2206A/SATURN3, BMBF; 01KD2206A/SATURN3, BMBF; 01KD2206A/SATURN3, BMBF; 01KD2206A/SATURN3)
DFG (CH 2320/2-3)
Deutsches Krebsforschungszentrum (DKFZ)
Article History
Received: 13 June 2022
Accepted: 22 November 2022
First Online: 9 December 2022
Declarations
:
: All relevant ethic approvals concerning use of patient material or mouse studies are appropriately mentioned in the supplementary methods section. Establishment of the PDX mouse model was performed using surgically resected PDAC tissues collected from patients at the Ruhr-University Bochum Comprehensive Cancer Center. Informed and written consent was obtained from all patients. The study was approved by the ethics committee of the Ruhr-University Bochum (permission nos. 3534–9, 3841–10, 16–5792). Patient tumor tissues were xenografted in both flanks of nude mice and expanded, isolated, and reimplanted for at least three generations. All animal experiments were performed according to the guidelines of the local Animal Use and Care Committees at the Ruhr-University Bochum (8.87–50.10.32.09.018, 84–02.04.2012.A328, and 81–02.04.2017.A423). For immunohistochemistry and multiplex immunofluorescence on human PDAC samples, a cohort of 31 patient samples from Radboud University Medical Center in Nijmegen, the Netherlands, was used. Given the retrospective nature of this study and the anonymized handling of data, informed consent was waived by the institutional review board (protocol CMO2018-4420). For HP-MRS animal experiments, approval of the animal protection and welfare review board was received prior to study initiation (ROB-55.2–2532.Vet_02-18–91). All experiments were carried out in adherence to pertinent laws and regulations.
: Not applicable.
: J. T. S. receives honoraria as consultant or for continuing medical education presentations from AstraZeneca, Bayer, Bristol-Myers Squibb, Immunocore, MSD Sharp Dohme, Novartis, Roche/Genentech, and Servier. His institution receives research funding from Abalos Therapeutics, Bristol-Myers Squibb, Celgene, Eisbach Bio, and Roche/Genentech; he holds ownership and serves on the Board of Directors of Pharma15, all outside the submitted work. DR received consultant and lecture fees from AstraZeneca, Merck Serono, Takeda, Pfizer, Novartis, Boehringer Ingelheim, Sanofi-Aventis, and BMS. DR received consultant and lecture fees from AstraZeneca, Merck Serono, Takeda, Pfizer, Novartis, Boehringer Ingelheim, Sanofi-Aventis, and BMS. DR is a founder and consultants of PearlRiver Bio GmbH and shareholder of Centessa Pharmaceuticals plc. DV reports the following: Gilead, Pfizer (advisory board), Bristol Myers Squibb (speaker’s honoraria), and AbbVie (travel support and congress registration fees). WW reports the following: advisory boards and speaker for Roche, MSD, BMS, AstraZeneca, Pfizer, Merck, Lilly, Boehringer, Novartis, Takeda, Bayer, Amgen, Astellas, Eisai, Illumina, Siemens, Agilent, ADC, GSK, and Molecular Health. Research funding is from Roche, MSD, BMS, and AstraZeneca. RV reports “pro bono” lectures and provides expert opinions at German court of law. The other authors declare that they have no competing interests.